Cite
HARVARD Citation
de la Fuente, M. et al. (2023). Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial. Neuro-oncology. 25 (1), pp. 146-156. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
de la Fuente, M. et al. (2023). Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial. Neuro-oncology. 25 (1), pp. 146-156. [Online].